FDA OKs first generic version of Trileptal

Oct 10, 2007

The U.S. Food and Drug Administration announced approval of the first generic versions of the anti-convulsion drug Trileptal (oxcarbazepine).

The FDA said it approved generic oxcarbazepine for use alone or in combination with other medications in the treatment of partial seizures in adults and children aged 4 years and older.

Oxcarbazepine tablets in three strengths (150 milligrams, 300 milligrams and 600 milligrams) are manufactured by Roxane Laboratories Inc., Glenmark Pharmaceuticals Ltd. and Sun Pharmaceutical Industries Ltd.

According to the publication Drug Topics, Trileptal was the 74th best selling brand-name drug by retail dollars in the United States last year.

Copyright 2007 by United Press International

Explore further: Anti-cholinergic drugs impair physical function in elderly patients

add to favorites email to friend print save as pdf

Related Stories

Drugmakers eliminate infant drops of key medicine

May 05, 2011

(AP) -- Johnson & Johnson and other makers of cold and fever medications said Wednesday that they will discontinue infant drops of medicines containing acetaminophen in an effort to avoid confusion that can lead to dangerous ...

FDA orders lower doses in prescription painkillers

Jan 13, 2011

(AP) -- Federal health regulators are limiting a key ingredient found in Vicodin, Percocet and other prescription painkillers that have been linked to thousands of cases of liver damage each year.

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments : 0